

20 mmol/L

≥ 2000 U/I

HDL-c direct FS*

Order Information

Cat. No.	Kit size	Instrument	\sum
1 3561 99 10 972	R1 3 x 18.3 mL	BX-3010 BX-4000	375 (3 x 125) 288 (3 x 96)
	R2 3 x 7.1 mL	BX-3010	375 (3 x 125)
		BX-4000	288 (3 x 96)

Intended Use

Diagnostic reagent for quantitative in vitro determination of HDL-C (high density lipoprotein cholesterol) in human serum or heparin plasma on automated Sysmex BX-Series.

Summary

Cholesterol, synthesized by body cells and absorbed with food, is a component of cell membranes and a precursor for steroid hormones and bile acids. Cholesterol is transported in plasma via lipoproteins. complexes between lipids and apolipoproteins. Four lipoprotein classes exist: High density lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins (VLDL) and chylomicrons. These classes show distinct relationship to coronary atherosclerosis. LDL is involved in the cholesterol transport to the peripheral cells, contributing to atherosclerotic plaque formation within the arterial intima and is strongly associated with coronary heart disease (CHD) and related mortality. HDL-C has a protective effect impeding plaque formation and shows an inverse relationship to CHD prevalence. In fact, low HDL-C values constitute an independent risk factor. One of the important functions of HDL involves the physiological removal of cholesterol from peripheral tissues and cells, and transport to the liver. The concept that HDL could protect against CHD primarily originated from epidemiological studies of the healthy population, in particular the Framingham study. In addition to a number of antioxidant effects, HDL also serves as a powerful mediator of the cellular inflammatory and antithrombotic responses. HDL-particles are macromolecule complexes synthesized by liver and intestine and formed from surface components. HDL-particles are released into plasma during lipolysis of lipoproteins rich in triglycerides. Particles consist of an amphipathic lipid monolayer of phospholipids and cholesterol with embedded amphipathic proteins surrounding a core of hydrophobic lipids, mostly cholesteryl esters and triglycerides. HDL-C monitoring is highly relevant in cardiovascular risk assessment. Elevated HDL-C levels usually correlate with decreased cardiovascular risk; whereas reduced concentrations of HDL-C, especially in combination with elevated triglycerides are associated with high risk of atherosclerotic heart disease, even at or below recommended LDL-C goals. Preferred screening tests for dyslipidemia or lipid disorders are total cholesterol (TC) and HDL-C but the majority of screening guidelines nowadays recommend a full lipid profile including TC, LDL-C, HDL-C and triglycerides. [1-8]

Method

Previous HDL-cholesterol determinations were performed by time-consuming precipitation methods or ultracentrifugation (reference method in combination with cholesterol measurement by Abell- Kendall). However, the direct determination of HDL-cholesterol is used in routine [9]. HDL-c direct FS is a homogeneous method for HDL-cholesterol measurement without centrifugation steps. Block polymer detergents protect LDL, VLDL and chylomicrons in a way that only HDL-cholesterol is selectively determined by an enzymatic cholesterol measurement [10].

The intensity of the formed dye is directly proportional to the cholesterol concentration and is measured photometrically.

Reagents

Components and Concentrations R1: Buffer

Peroxidase (POD)

	i cioxidase (i OB)		- 2000 O/L
	N-(2-hydroxy-3-sulfopropyl)-		≥ 0.7 mmol/L
	3,5-dimethoxyaniline sodium s	alt	
	(H-DAOS)		
R2:	Buffer	pH 8.15	20 mmol/L
	Cholesterol esterase (CHE)	·	≥ 400 U/L
	Cholesterol oxidase (CHO)		≥ 700 U/L
	Peroxidase (POD)		≥ 15000 U/L
	4-Aminoantipyriné		≥ 1.5 mmol/L

pH 6.85

Storage and Stability

Reagents are stable up to the date of expiry indicated on the kit, if stored at $2-8^{\circ}C$ and contamination is avoided. Do not freeze and protect from light.

The in-use stability of the reagent is 24 months.

Warnings and Precautions

 Components contained in HDL-c direct FS are classified according to EC regulation 1272/2008 (CLP) as follows:



Reagent 1: Warning. Contains Mixture of 5-chlorine-2-methyl-2H-isothiazol-3-on and 2-methylen-2H-isothiazol-3-on (3:1). H317 May cause an allergic skin reaction. P280 Wear protective gloves/protective clothing/eye protection. P302+P352 IF ON SKIN: Wash with plenty of water/soap.

- Reagent 2 contains sodium azide (0.95 g/L) as preservative. Do not swallow! Avoid contact with skin and mucous membranes.
- The reagents contain material of biological origin. Handle the product as potentially infectious according to universal precautions and good clinical laboratory practice.
- Acetaminophen and metamizole medication leads to falsely low results in patient samples.
- In very rare cases, samples of patients with gammopathy might give falsified results [11].
- In case of product malfunction or altered appearance that could affect the performance, contact the manufacturer.
- Any serious incident related to the product must be reported to the manufacturer and the competent authority of the Member State where the user and/or patient is located.
- Please refer to the safety data sheets (SDS) and take the necessary precautions for the use of laboratory reagents. For diagnostic purposes, the results should always be assessed with the patient's medical history, clinical examinations and other findings.
- 9. For professional use only.

Waste Management

Refer to local legal requirements for chemical disposal regulations as stated in the relevant SDS to determine the safe disposal.

Warning: Handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Reagent Preparation

The reagents are ready to use. The bottles are placed directly into the reagent rotor.

Materials Required

General laboratory equipment

HDL-c direct FS – Page 1 844 3561 41 02 00 October 2022/2

Specimen

Human serum or lithium heparin plasma

Only use suitable tubes or collection containers for specimen collection and preparation.

When using primary tubes, follow the manufacturer's instructions.

Stability [12]:

2 days at 20 – 25°C 7 days at 4 – 8°C 3 months at –20°C

Only freeze once. Discard contaminated specimens.

Calibrators and Controls

DiaSys TruCal Lipid is recommended for calibration. Calibrator values have been made traceable to a commercially available assay, which is standardized against the designated CDC reference method (ultracentrifugation method). Use DiaSys TruLab L Level 1 and Level 2 for internal quality control. Quality control must be performed after calibration. Control intervals and limits have to be adapted to the individual requirements of each laboratory. Results must be within the defined ranges. Follow the relevant legal requirements and guidelines. Each laboratory should establish corrective action in case of deviations in control recovery.

	Cat. No.		Kit si	ize
TruCal Lipid	1 3570 99 10 045	3	Χ	2 mL
TruLab L Level 1	5 9020 99 10 065	3	Χ	3 mL
TruLab L Level 2	5 9030 99 10 065	3	Х	3 mL

Performance Characteristics

Measuring range up to 200 mg/dL (5.17 mmol/L). In case of higher concentrations re-measure samples after manual dilution with NaCl solution (9 g/L) or use rerun function.					
Limit of detection**	3 mg/dL (0.078 mmol/L)				
Onboard stability	18 weeks				
Calibration stability 14 weeks					

Interfering substance	Interferences ≤ 9% up to	Analyte concentration	
Ascorbic acid	60 mg/dL	31.7 mg/dL (0.819 mmol/L)	
	60 mg/dL	78.6 mg/dL (2.03 mmol/L)	
Bilirubin (conjugated)	40 mg/dL	34.0 mg/dL (0.880 mmol/L)	
	50 mg/dL	75.8 mg/dL (1.96 mmol/L)	
Bilirubin (unconjugated)	60 mg/dL	34.9 mg/dL (0.903 mmol/L)	
	60 mg/dL	83.2 mg/dL (2.15 mmol/L)	
Hemoglobin	800 mg/dL	35.8 mg/dL (0.925 mmol/L)	
	1000 mg/dL	77.9 mg/dL (2.01 mmol/L)	
N-acetylcysteine (NAC)	1700 mg/L	31.1 mg/dL (0.805 mmol/L)	
	1700 mg/L	80.3 mg/dL (2.08 mmol/L)	
Lipemia (triglycerides)	1000 mg/dL	33.3 mg/dL (0.860 mmol/L)	
	1600 mg/dL	68.1 mg/dL (1.76 mmol/L)	

For further information on interfering substances refer to Young DS [13,14].

Precision			
Within run (n=20)	Sample 1	Sample 2	Sample 3
Mean [mg/dL]	20.0	39.5	199
Mean [mmol/L]	0.516	1.02	5.14
CV [%]	1.42	0.772	1.61
Between day (n=20)	Sample 1	Sample 2	Sample 3
Mean [mg/dL]	19.4	39.2	195
Mean [mmol/L]	0.502	1.01	5.05
CV [%]	1.53	1.88	2.12

Method comparison (n= 132)				
Test x	DiaSys HDL-c direct FS (BioMajesty® JCA-BM6010C)			
Test y	DiaSys HDL-c direct FS (BX-3010)			
Slope	1.01			
Intercept	-0.708 mg/dL (-0.018 mmol/L)			
Coefficient of correlation	0.999			

^{**} lowest measurable concentration which can be distinguished from zero; mean + 3 SD (n = 20) of an analyte free specimen.

Conversion Factor

 $HDL-C [mg/dL] \times 0.02586 = HDL-C [mmol/L]$

Reference Range [15]

National Cholesterol Education Program (NCEP) guidelines:

Low HDL-cholesterol (major risk factor for CHD):

< 40 mg/dL (< 1.04 mmol/L)

High HDL-cholesterol ("negative" risk factor for CHD):

≥ 60 mg/dL (≥ 1.55 mmol/L)

A number of factors contribute to low HDL-cholesterol levels: e.g. overweight and obesity, smoking, physical inactivity, drugs such as beta-blockers and progestational agents, genetic factors.

Each laboratory should check if the reference ranges are transferable to its own patient population and determine own reference ranges if necessary.

Literature

- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASP C/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.
- Gordon DJ, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease. Four Prospective American Studies. Circulation. 1989;79:8-15.
- Favari E, Chroni A, Tietge UJF et al. Cholesterol Efflux and Reverse Cholesterol Transport. In: Eckardstein A and Kardassis D, editors. High Density Lipoproteins: From Biological Understanding to Clinical Exploitation. Springer; 2015. page 181-206.
- Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circulation research. 2004;95:764-772.
- Lee JS, Chang PY, Zhang Y, et al. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. Diabetes Care. 2017;40:529-537.
- Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceriderich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European heart journal volume. 2011;32:1345-61.
- Rifai N, Warnwick GR. Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors. In: Burtis CA, Ashwood ER and Burns DE, editors. Tietz Textbook of Clinical Chemistry. 4th ed. Missoury: Elsevier Saunders company; 2006. page 903-981.
- Task Force Report of European and other Societies on Coronary Prevention. Recommendation of the Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. European Heart Journal; 1998. Report No.: hj981243.

- Langlois MR, Blaton VH. Historical milestones in measurement of HDLcholesterol: Impact on clinical and laboratory practice. Clin Chimica Acta. 2006;369:168-178.
- Miida T, Nishimura K, Okamura T, et al. Validation of homogeneous assays for HDL-cholesterol using fresh samples from healthy and diseased subjects. Atherosclerosis. 2014; 233(1):253-9.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. ClinChemLabMed. 2007;45(9):1240-1243.
- Guder WG, da Fonseca-Wollheim F, Heil W, et al. The Quality of Diagnostic Samples. 3rd ed. Darmstadt: GIT Verlag; 2010. p. 22-3.
- p. 22-3.
 13. Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th ed. Volume 1 and 2. Washington DC: The American Association for Clinical Chemistry Press; 2000.
- Young DS. Effects on Clinical Laboratory Tests Drugs Disease, Herbs & Natural Products [Internet]. AACC Press and John Wiley and Sons, Inc; 2020 [cited 2020 May]. Available from: https://clinfx.wiley.com/ aaccweb/aacc/
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.

Additions and/or changes in the document are highlighted in grey. For deletions, please refer to the customer information for the corresponding edition number of the package inserts.





DiaSys Diagnostic Systems GmbH Alte Strasse 9 65558 Holzheim Germany www.diasys-diagnostics.com

* Fluid Stable

HDL-c direct FS – Page 3 844 3561 41 02 00 October 2022/2

Chemistry Parame	eters 1				Svsm	ex BX-3010 Che	mistry Analyzer
							ical Parameters
Method No.	*	Method Name	HDL-CD		Reagent Name	Reagent (μL)	Water (µL)
Print Name	HDL-CD	MethodColor		R1	HDL-CD	120	
Sample Type	Serum			R2	HDL-CD	30	
Unit	mg/dL			Diluent	Disable		
Assay Type	End		Samp	le Ppt. Wash	Disable		
Measuring points		Start Er	nd Stirri	ng Speed R1	Middle	R2 Middle	
	1	22 –	23				
	2	45 –	46				
				Normal Rand	ie ial Range Name	Min	Max
Wave Length	im. 600	Sec. 700		1 Male		*	*
		OGC. <u> 700</u>		3 Male	-G3	*	*
				4 Fema	ale-G1	*	*
Normal Sampl Low	e Volume (μL) Normal Hi	Diluted Sample (μL)	Diluent (μL)	Technical Ra	ange (Cond	c) 3 -	- 200
□ Diluent 0.0	< 1.5 < 0	.0]	(mAbs/10		*
Rerun (High/Prozo ☐ Diluent 0.0		.0		Previous Re	esult Comparison (%	b) *	* %
Rerun (Low)				Abnormal R			
Diliderit 0.0	< 1.5 < 0	.0		<u>-1</u> 1	,		
				Panic Rang	•		
					Decimal Poi	nt 2 Profile S	Disable
*Entered by user	r						
Chemistry Parame	eters 2				Sysm	ex BX-3010 Che	mistry Analyzer
-					-		ical Parameters
Method No	o. * Method	Name HDL-CD		S	Sample Serum		
Limit Checks				Blank measure	ement		
✓ Duplicate Limit	100	mAbs/10		Blank mea	surement: eagent blank and C1	blank	
✓ Sensitivity Limit	2000	mAbs/10		<u></u>	ent of Reagent Blan		
✓ Linearity Limit		%		None	and a reagon blun	23	
		(mAbs/10)/min			lank measurement a	at calibration:	
□ Prozone Limit		%		Reagent b	olank (No sample)		
				The number	er of measurement:		
,	SL1-S	_ SL1-F			lank limit checks:	<u>-</u>	
`	JL1-0		<u></u> "	Duplicate I		50	mAbs/10

Absorbance Limit

SL2-S

Limit

Sensitivity

Abs. in reaction

SL2-F


mAbs/10

mAbs/10

Instrument Factor

a 1.00

b 0.00



<u>Chemistry Parameters</u> Sysmex BX-4000 Chemistry Analyzer						
		.		llytical Parameters		
Method * Name HDL-CD		Reagent Name	Reagent (μL)	Water (μL)		
Print Name HDL-CD	R1	HDL-CD	160	I		
Sample	R2 ✓ Ena	able HDL-CD	40			
Unit mg/dL						
Assay Type End	Diluent □ Er	nable				
Measuring points Start E	End Decimal Poir	nts 2				
1 33 -	34					
☐ Enable 2 67 —	68					
	Normal Ra	ange Normal Range Name	Min	Max		
Wave Length Prim. 600 Sec □ Disable 70		ale-G1 ale-G2	*	*		
1 11111 000 1 1 1 1 1 1 1 1 1 1 1 1 1 1	3 Ma	ıle-G3	*	*		
	4 Fe	male-G1	*	*		
	Diluent (μL) Te	echnical Range	nc) 3.0	- 200		
Rerun (High/Prozone)		(mAbs/		_ *		
Dilution 2 Rerun (Low)	0					
	0	T Wash	Reagent Name			
SPT Wash ☐ Enable						
Stirring Speed R1 Middle R2 Middle						
*Entered by user						
<u>Chemistry Parameters</u> Sysmex BX-4000 Chemistry Analyzer						
	lr-		Ana	lytical Parameters		
	Serum					
Limit Checks	В	lank measurement				
✓ Duplicate Limit 100 mAbs/10		Blank measurement: Disable reagent blank an	d S1 blank			
✓ Sensitivity Limit 2000 mAbs/10		Measurement of Reagent I	Blank during Run:			
✓ Linearity Limit %	(mAbs/10)/min	None	Julia Garrig Carr			
□ Prozone Limit % Upper	r	Reagent blank measureme Reagent blank (No samp				
SL1-S		The number of measureme	ent:			
SL2-S SL2-F		Duplicate				
Sensitivity mAbs/10	✓	Reagent blank limit checks Duplicate Limit	50	mAbs/10		
✓ Absorbance Limit						

Reaction

Limit

mAbs/10

Instrument Factor

a 1.00

b 0.00

